Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis.

Xolair (omalizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42714921

Alhasan Altayf; Muhammed Elhadi; Mukhtar Alwefati; Pavel Kolkhir; Pedro Mendes-Bastos; Ranad Jirafa; Torsten Zuberbier

Sep 10, 2026